{Reference Type}: Case Reports
{Title}: Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report.
{Author}: Lisowski D;Hartrampf PE;Hasenauer N;Nickl V;Monoranu CM;Tamihardja J;
{Journal}: BMC Neurol
{Volume}: 23
{Issue}: 1
{Year}: 2023 Nov 4
{Factor}: 2.903
{DOI}: 10.1186/s12883-023-03450-w
{Abstract}: <B>BACKGROUND: </B>Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis.<BR><B>METHODS: </B>We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment.<BR><B>CONCLUSIONS: </B>E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.